Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Reflections on the Innovative Medicines Initiative

Nature Reviews Drug Discovery volume 10, pages 321–322 (2011)Cite this article

Subjects

An Erratum to this article was published on 01 June 2011

Abstract

The pharmaceutical industry is developing new collaborative models for drug development. This article discusses the experience so far of the Innovative Medicines Initiative, which is currently the largest public–private partnership that is dedicated to pharmaceutical innovation, highlighting lessons learned for the success of precompetitive consortia.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Abbott, A. The drug deadlock. Nature 468, 158–159 (2010).

    Article  CAS  Google Scholar 

  2. Bel, E. H. et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 23 Nov 2010 (doi:10.1136/thx.2010.153643).

Download references

Acknowledgements

I would like to thank S. Black, K. De Rijck, A. Juliens and M. Poinot for their valuable assistance in the preparation of the paper, and A. Smith for his critical reading of the manuscript and useful suggestions.

Author information

Authors and Affiliations

  1. Michel Goldman is Executive Director of the Innovative Medicines Initiative, B-1060 Brussels, Belgium.,

    Michel Goldman

Authors
  1. Michel Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Goldman.

Ethics declarations

Competing interests

Michel Goldman is the Executive Director of the Innovative Medicines Initiative.

Supplementary information

Supplementary information Table S1

Ongoing projects of the Innovative Medicines Initiative in 2011 (PDF 299 kb)

Supplementary information Box S2

Intellectual property in the Innovative Medicines Initiative (PDF 242 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldman, M. Reflections on the Innovative Medicines Initiative. Nat Rev Drug Discov 10, 321–322 (2011). https://doi.org/10.1038/nrd3434

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3434

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research